Abstract
Nowadays human pancreatic islet transplantation is a therapeutic approach in kidney transplanted patients with type 1 diabetes having severe macrovascular disease. Because of its low morbidity compared to pancreas transplantation, islet transplantation can be also proposed to patients with brittle type 1 diabetes and severe hypoglycemic events despite intensive insulin therapy. Evaluation of glucose instability is crucial for the optimal selection of candidates and to assess the benefit/risk ratio. The main objective of islet transplantation is not to reverse diabetes but to restore a satisfactory glucose control aiming to improve the clinical management and the quality of life. Further clinical trials with new immunosuppressive drugs are needed in order to improve the efficiency of islet transplantation and to apply this treatment to a large number of patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
